X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The proceeds will advance company's late-stage clinical programs, including UX143 (setrusumab), an investigational, fully human mAb that inhibits sclerostin, support commercial launch, and advance its preclinical pipeline through IND applications into clinical development.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $326.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 23, 2023
Details:
The proceeds will advance company's late-stage clinical programs, including UX143 (setrusumab), an investigational, fully human mAb that inhibits sclerostin, support commercial launch, and advance its preclinical pipeline through IND applications into clinical development.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 18, 2023
Details:
The proceeds will advance company's late-stage clinical programs, including UX143 (setrusumab), an investigational, fully human mAb that inhibits sclerostin, support commercial launch, and advance its preclinical pipeline through IND applications into clinical development.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 17, 2023
Details:
UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mereo BioPharma Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2023
Details:
UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mereo BioPharma Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Setrusumab (UX143) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the activity of bone-forming cells.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mereo BioPharma Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
Orbit study builds on finding of 12-month Phase 2b ASTEROID study, which demonstrated that treatment with setrusumab resulted in clear, dose-dependent and statistically significant effect on bone formation and bone density at multiple anatomical sites among adult participant.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: UX143
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Ultragenyx will lead future global development of setrusumab in both pediatric and adult patients. Mereo granted Ultragenyx an exclusive license to develop and commercialize setrusumab in the US and rest of the world, excluding Europe where Mereo retains commercial rights.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: BPS-804
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ultragenyx Pharmaceutical
Deal Size: $304.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration December 17, 2020
Details:
In Mereo’s Phase 2b ASTEROID study, setrusumab demonstrated a dose-dependent bone building effect and a trend of reduction in fractures in addition to being safe and well tolerated in adults with OI.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: BPS-804
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Setrusumab demonstrated a dose dependent increase in both failure load and stiffness at the radius at 12 months, achieving statistical significance in the high dose cohort.
Lead Product(s): Setrusumab
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
